Last week’s hot topic on Cystic Fibrosis titled Cystic Fibrosis Compound to Stabilize CFTR Protein Advances in Clinical Study was written by Daniela Semedo.
The article focuses on Nivalis Therapeutics, Inc., recently announcing an expanded clinical development plan for N91115, the company’s first-in-class stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is defective in patients with cystic fibrosis (CF).
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?